Cambridge Nutranostics

Cambridge Nutranostics is a private UK biotechnology and diagnostics company developing point-of-care tests that measure oxygen-carrying capacity in blood plasma. Its lead technology is the OCCL test prototype, designed to use a drop of capillary blood to assess plasma oxygen changes that may support early monitoring of pregnancy health and other conditions associated with impaired tissue oxygenation. Publicly available information indicates the company is an active private limited company incorporated in 2014 and classified under biotechnology R&D. The business appears to be focused on translational diagnostic development rather than a broad therapeutic drug pipeline.